Group sequential and discretized sample size re-estimation designs: a comparison of flexibility.
In clinical trials, researchers usually determine a study sample size prior to the start of the study to provide a sufficient power at a targeted treatment difference. When the targeted treatment difference deviates from the true one, the study may either have insufficient power or use more subjects than necessary. To address the difficulty in sample size planning, researchers have developed various flexible sample size designs and compared their performances. Some previous work suggests that re-estimation designs are inefficient and that one can improve uniformly by using standard group sequential likelihood ratio tests, although more interim analyses are involved. However, researchers need to further study the statement and the minimal number of tests needed before a standard group sequential test might outperform a re-estimation design. In this paper, we conducted simulation studies to answer these questions using various optimality criteria.
Gilead Sciences Inc., Foster City, CA 94404, USA. xiaoru.wu@gmail.com
Xiaoru
X
Wu
Lu
L
Cui
D001943:Breast Neoplasms / Q000517:prevention & control; D002986:Clinical Trials as Topic / Q000379:methods*; D005260:Female; D006801:Humans; D009716:Numerical Analysis, Computer-Assisted; D012107:Research Design; D018401:Sample Size; D013629:Tamoxifen / Q000627:therapeutic use; D016896:Treatment Outcome
D013629:Tamoxifen